On February 28, 2023, Dr. Gregory M. Glenn, M.D. notified Novavax Inc. of his decision to retire as President, Research and Development, effective as of March 31, 2023. The Company intends to retain Dr. Glenn as the Company's Strategic Research & Development Advisor, providing consulting services to the Company following his retirement.
Market Closed -
Other stock markets
|
After market 04:37:12 pm | |||
4.09 USD | +3.54% | 4.085 | -0.12% |
Apr. 15 | Sector Update: Health Care Stocks Gain Monday Afternoon | MT |
Apr. 15 | Global markets live: Goldman Sachs, Apple, Salesforce, Boeing Tesla... |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.79% | 553M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- NVAX Stock
- News Novavax, Inc.
- Novavax Inc. Announces the Retirement of Gregory M. Glenn, M.D. as President, Research and Development, Effective as of March 31, 2023